This study is in progress, not accepting new patients
Trial of Pamrevlumab (FG-3019), in Non-Ambulatory Subjects With Duchenne Muscular Dystrophy (DMD)
Summary
- Eligibility
- for males ages 12 years and up (full criteria)
- Location
- at San Francisco, California and other locations
- Dates
- study startedestimated completion
- Principal Investigator
- by Jonathan Strober
Description
Summary
Official Title
Details
Keywords
Eligibility
Locations
Lead Scientist at UCSF
- Jonathan Strober
Professor, Neurology. Authored (or co-authored) 49 research publications.
Details
- Status
- in progress, not accepting new patients
- Start Date
- Completion Date
- (estimated)
- Sponsor
- FibroGen
- ID
- NCT02606136
- Phase
- Phase 2
- Study Type
- Interventional
- Last Updated